Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ono Aims at Sales of ¥10 Bil. for Emend
December 6, 2010
- Need for Closer Cooperation Reconfirmed at 4th THMM
December 6, 2010
- Major Dispensing Pharmacy Chains Introduce More Automatic Dispensing Systems
December 6, 2010
- EPS: Sales Up 25% Driven by CSO Business
December 6, 2010
- Efficacy Not Confirmed for NV1FGF in PIII: AHA
December 6, 2010
- Use of Points for Out-of-Pocket Payments Unacceptable: JPA
December 6, 2010
- Safety, Efficacy of Anacetrapib Confirmed in PIII: AHA
December 6, 2010
- Novartis, sanofi-aventis to Copromote Equa
December 6, 2010
- BMS, Pfizer Discontinue Apixaban Development for ACS
December 6, 2010
- Shionogi Leads IP Assets Ranking Followed by Kyowa Kirin
December 6, 2010
- Kyowa Kirin to Present KW-0761 Results at ASH
December 6, 2010
- Janssen Resumes Supply of Velcade
December 6, 2010
- BI Publishes Dabigatran Sub-Group Analysis
December 6, 2010
- Popular Name Made Legal Name: InCROM
December 6, 2010
- OncoTherapy Starts Clinical Trial for Gastric Tumor Vaccine
December 6, 2010
- NHI Pricing Recommended for Xyzal, Byetta
December 6, 2010
- PAFSC Withholds Recommending Switch OTC Version of Epadel
December 6, 2010
- Oral Ketotifen Products Should Remain in Class 1: JPA
November 29, 2010
- Bristol-Myers Required to Develop Largest Number of Unapproved Drugs/Indications
November 29, 2010
- 64 Amaryl Generics from 28 Companies Listed
November 29, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…